- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 05.01. | Novo's Wegovy pill makes US debut, with starter dose launching at $149 per month for cash-paying patients | ||
| 05.01. | Incyte to seek FDA approval for 7-drug Monjuvi regimen in 1st-line diffuse large B-cell lymphoma | ||
| 02.01. | Vanda's motion sickness drug, Agios' thalassemia treatment make the grade with FDA | ||
| 02.01. | Pacira brings Exparel DTC campaign to life with family-focused NYC event | ||
| 02.01. | Foresee Pharmaceuticals spots prostate cancer med's potential in rare puberty disease, touts phase 3 win | ||
| 02.01. | After scrapped trial, InflaRx could tap partner to revive development of COVID drug in rare skin disorder | ||
| 02.01. | Verastem nixes KRAS G12C plans in non-small cell lung cancer | ||
| 02.01. | Regulatory tracker: Outlook Therapeutics' ophthalmic bevacizumab hit with another FDA rejection | ||
| 29.12.25 | Acquisitive Sanofi keeps deals coming, laying out $2.2B for hepatitis vaccine maker Dynavax | ||
| 26.12.25 | Omeros scores its first-ever FDA nod as stem cell transplant drug Yartemlea approved | ||
| 23.12.25 | Baltimore jury orders J&J to pay $1.5B in largest-ever award to a talc plaintiff | ||
| 23.12.25 | Pfizer confirms patient death in Hympavzi hemophilia extension study | ||
| 23.12.25 | Neurocrine's Ingrezza fails phase 3 trial for cerebral palsy | ||
| 23.12.25 | What a year: Here are the stories that captivated our audience in 2025 | ||
| 23.12.25 | AstraZeneca, betting on radiopharmaceuticals, extends Niowave isotope supply deal by 10 years | ||
| 22.12.25 | FDA comes bearing gifts early for Cytokinetics and blockbuster-to-be Myqorzo | ||
| 22.12.25 | BI's Jascayd quickly expands lung disease reach with new FDA nod | ||
| 22.12.25 | Turning up the volume on colorectal cancer awareness drives diagnosis in Nigeria | ||
| 22.12.25 | With FDA approval, Roche's blood cancer bispecific Lunsumio goes subcutaneous | ||
| 22.12.25 | ALS med Radicava to change hands as Shionogi inks $2.5B buyout | ||
| 22.12.25 | Incog to spend $200M on capacity boost at Indiana sterile injectables plant | ||
| 22.12.25 | Samsung Biologics pays GSK $280M to secure first US manufacturing site | ||
| 19.12.25 | 9 pharma giants reach US drug price deals with Trump administration | ||
| 19.12.25 | AstraZeneca to pull bleeding reversal agent Andexxa after FDA flags risk imbalance | ||
| 19.12.25 | FDA outlined concerns with Elevidys manufacturing at Catalent site, Form 483 shows |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .